genome pharmaceuticals

What genome pharmaceuticals does

Genome Pharmaceuticals is a privately-held Pakistani pharmaceutical manufacturer headquartered in Islamabad, with production concentrated at a 50,000 square foot WHO cGMP-compliant facility in Hattar, Haripur (Khyber Pakhtunkhwa). The company manufactures and distributes a portfolio of approximately 300-500 registered pharmaceutical products across five dosage forms (tablets, capsules, dry suspensions, injectables, sachets) spanning cardiovascular, anti-infective (including hepatitis C direct-acting antivirals and antimalarials), neurology and psychiatry, gastroenterology, dermatology, diabetes, and oncology therapeutic areas. Manufacturing is supported by an in-house R&D and regulatory affairs function operating under Good Laboratory Practice (GLP) standards, with stated expertise in drug delivery technologies and experience bringing new products to global markets.

The business operates three revenue streams: domestic manufacturing and distribution of branded generics through a nationwide sales and marketing network within Pakistan; export of finished formulations to international buyers in Sri Lanka, Afghanistan, Vietnam, Cambodia, and Myanmar; and contract manufacturing services offered to overseas pharmaceutical clients. Pricing is not publicly disclosed. Manufacturing execution is anchored by computerized production control systems, advanced factory automation, ongoing GMP training for Production, QA, Engineering, and warehouse personnel, and a quality management system covering raw material procurement through logistics.

The company is positioning for geographic expansion into additional South Asian (Laos), Southeast Asian (Philippines), East African (Kenya, Uganda, Rwanda, Somalia), West African (Nigeria), Middle Eastern (Yemen), and CIS markets, alongside continued branded generics development. No external funding, parent company, public listing, patents, named customers, management team, or headcount figures are disclosed in the available source material; ownership appears to be independent and founder-controlled.

Name

genome pharmaceuticals

Legal name

Genome Pharmaceuticals

Website

https://genomepharmaceuticals.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Genome Pharmaceuticals is a Pakistan-based pharmaceutical manufacturer producing tablets, capsules, dry suspensions, injectables, and sachets across cardiovascular, infectious disease, neurology, and oncology categories, distributing domestically and exporting to markets in South Asia, Southeast Asia, and Africa.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Contract manufacturing
• Pharmaceutical exports
• CGMP production

Headquarters

HQ city

Rawalpindi

HQ country

Pakistan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Manufacturing: Manufacturing and selling proprietary pharmaceutical products including tablets, capsules, dry suspensions, injectables, and sachets across various therapeutic areas.
2. Export Operations: Export of pharmaceutical products to international markets including Sri Lanka, Afghanistan, Vietnam, Cambodia, Myanmar with expansion to Laos, Kenya, Uganda, Philippines, Rwanda, Nigeria, Somalia, Yemen, and CIS countries.
3. Contract Manufacturing: Provides contract manufacturing facility to overseas clients, offering production capabilities for third-party pharmaceutical products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Genome Pharmaceuticals manufactures and exports pharmaceutical products across multiple therapeutic areas in tablet, capsule, dry suspension, injectable, and sachet dosage forms from its WHO cGMP-compliant manufacturing facility in Pakistan. The company operates a nationwide sales and marketing network within Pakistan and an export department serving international markets, while also providing contract manufacturing facilities and marketing operations assistance to overseas pharmaceutical clients.

Product overview

Genome Pharmaceuticals operates as a pharmaceutical manufacturing, import, and export company based in Pakistan. The company produces a portfolio of approximately 500 pharmaceutical products across multiple therapeutic areas, organized into five primary dosage forms: tablets, capsules, dry suspensions, injectables, and sachets. Their product portfolio spans cardiovascular medications (including statins like Rosuvastatin products and antihypertensives), anti-infectives (antibiotics, antivirals including Hepatitis C treatments like Sofosbuvir and Daclatasvir, and antimalarials like Artemether/Lumefantrine combinations), neurological/psychiatric medications (including Pregabalin for neuropathic pain, Memantine for Alzheimer's, and Quetiapine for schizophrenia), gastrointestinal products (proton pump inhibitors like Dexlansoprazole DDR capsules), and specialty products including dermatological treatments (Isotretinoin), diabetes medications (Sitagliptin-based products), and oncology chemotherapeutics (Gemcitabine infusions). The company maintains WHO cGMP compliant manufacturing facilities spanning 50,000 square feet and exports to multiple international markets including Sri Lanka, Afghanistan, Vietnam, Cambodia, and Myanmar.

Differentiator

Problem solved

Functional benefit

Products and services

• Demantin (Memantine) Memantine hydrochloride tablets (10mg and 20mg) used for the treatment of Alzheimer's disease and cognitive disorders.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Aurobindo Pharma: Indian pharmaceutical company with extensive generic manufacturing across multiple dosage forms including injectables, broad emerging market presence, and competitive presence in tenders for anti-infectives and chronic disease medications similar to Genome's portfolio.
• Hetero Drugs: Indian generic manufacturer with strong ARV, Hepatitis C, and oncology portfolios, significant WHO PQ certifications, and large emerging-market export presence directly competing with Genome in HIV and Hep C product categories.
• Cipla: Indian pharmaceutical major with extensive generic portfolio across respiratory, anti-infectives, cardiovascular, and HIV/malaria, dominating emerging market exports including many of the same African and Southeast Asian geographies Genome targets.
• Dr. Reddy's Laboratories: Indian multinational pharmaceutical company producing generics across multiple therapeutic areas including gastrointestinal (PPIs like Dexlansoprazole), anti-infectives, and oncology, with established global export operations.

Direct peers

• Searle Pakistan: Pakistan-listed pharmaceutical company manufacturing and marketing branded generics with manufacturing facilities and regional export presence, operating in directly overlapping therapeutic categories and dosage forms.
• AGP Limited: One of Pakistan's largest pharmaceutical manufacturers producing generics across multiple therapeutic areas with cGMP manufacturing and export operations, comparable in product portfolio breadth and export orientation.
• Ferozsons Laboratories: Pakistani pharmaceutical manufacturer with WHO cGMP facilities, producing generics and specialty products including antimalarials and vaccines, with export operations to regional markets similar to Genome's footprint.
• Hilton Pharma: Pakistani pharmaceutical company manufacturing generics across therapeutic categories including anti-infectives, cardiovascular, and neurology, with similar dosage form capabilities (tablets, capsules, injectables) and export operations to emerging markets.
• Getz Pharma: Pakistan-based pharmaceutical manufacturer producing branded generics across multiple therapeutic areas with WHO cGMP facilities and an export footprint to emerging markets in Africa, Asia, and the CIS region, directly comparable to Genome in scale, product breadth, and target geographies.

Regional players

• Renata Limited (Bangladesh): Bangladeshi pharmaceutical manufacturer with WHO cGMP facilities producing generics and animal health products, exporting across South/Southeast Asia and Africa, comparable to Genome as a South Asian emerging-market generic exporter with similar product breadth.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genome-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about genome pharmaceuticals